Skip to main content
Midas Edge

Gain Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

GANX$1.08-0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statement of Stockholders’ Equity (Unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

​​​​​​​​​​​​​
​ · ​ · Common Stock · ​ · APIC · AOCI · ​ · Accumulated · ​ · Total
Six Months Ended June 30, 2024 · ​ · Shares · Amounts · ​ · ​ · Deficit · ​
Balance as of December 31, 2023​16,206,680$1,621$73,113,079$247,241$(60,783,717)$12,578,224
Stock-based compensation (Note 14)​35,983​3​1,578,329​—​—​1,578,332
Exercise of stock options (Note 14)​15,983​2​57,709​—​—​57,711
Exercise of warrants (Note 13)​1,797,380​180​113,621​—​—​113,801
Issuance of shares and warrants in public offering (Note 13)​7,116,547​712​9,848,009​—​—​9,848,721
Defined benefit pension plan (Note 10)​​​—​—​2,176​—​2,176
Foreign currency translation​​​—​—​(241,929)​—​(241,929)
Net unrealized gain on available for sale securities (Note 4)​​​—​—​4,974​—​4,974
Net loss​​​—​—​—​(12,157,272)​(12,157,272)
Balance as of June 30, 2024​25,172,5732,51884,710,74712,462(72,940,989)11,784,738
​​​​​​​​​​​​​
​​Common Stock​APICAOCI​Accumulated​Total
Three Months Ended June 30, 2024​SharesAmounts​​Deficit​
Balance as of March 31, 2024​18,041,231$1,805$73,416,304$21,863$(64,797,911)$8,642,061
Stock-based compensation (Note 14)​4,858​—​1,432,859​—​—​1,432,859
Exercise of stock options (Note 14)​​​—​—​—​—​—
Exercise of warrants (Note 13)​9,937​1​13,575​—​—​13,576
Issuance of shares and warrants in public offering (Note 13)​7,116,547​712​9,848,009​—​—​9,848,721
Defined benefit pension plan (Note 10)​​​—​—​1,090​—​1,090
Foreign currency translation​​​—​—​(11,137)​—​(11,137)
Net unrealized gain on available for sale securities (Note 4)​​​—​—​646​—​646
Net loss​​​—​—​—​(8,143,078)​(8,143,078)
Balance as of June 30, 2024​25,172,5732,51884,710,74712,462(72,940,989)11,784,738

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

​​​​​​​​​​​​​
​ · ​ · Common Stock · ​ · APIC · ​ · AOCI · ​ · Accumulated · ​ · Total
Six Months Ended June 30, 2023 · Shares · Amounts · ​ · ​ · Deficit · ​
Balance as of December 31, 2022​11,883,368$1,189$57,358,895$35,627$(38,516,197)$18,879,514
Stock-based compensation​67,400​6​1,949,708​—​—​1,949,714
Issuance of shares in at-the-market (ATM) offering​681,559​68​2,990,130​—​—​2,990,198
Defined benefit pension plan​​​—​—​(1,370)​—​(1,370)
Foreign currency translation​​​—​—​58,051​—​58,051
Net unrealized gain on available for sale securities​​​—​—​42,015​—​42,015
Net loss​​​—​—​—​(12,825,288)​(12,825,288)
Balance as of June 30, 2023​12,632,327​1,263​62,298,733​134,323​(51,341,485)​11,092,834
​​​​​​​​​​​​​
​​​​​​​​​​​​​
​​Common Stock​APIC​AOCI​Accumulated​Total
Three Months Ended June 30, 2023SharesAmounts​​Deficit​
Balance as of March 31, 2023​12,087,142$1,209$58,694,827$96,310$(43,653,516)$15,138,830
Stock-based compensation​67,400​6​1,384,276​—​—​1,384,282
Issuance of shares in at-the-market (ATM) offering​477,785​48​2,219,630​—​—​2,219,678
Defined benefit pension plan​​​—​—​(700)​—​(700)
Foreign currency translation​​​—​—​39,960​—​39,960
Net unrealized loss on available for sale securities​​—​—​(1,247)​—​(1,247)
Net loss​​—​—​—​(7,687,969)​(7,687,969)
Balance as of June 30, 2023​12,632,327​1,263​62,298,733​134,323​(51,341,485)​11,092,834
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.